摘要
目的探讨布拉氏酵母菌辅助含铋剂四联疗法对幽门螺杆菌(Hp)首次根除失败消化性溃疡(PU)患者的治疗效果及其对Hp根除率、复发率的影响。方法选取2020年2月至2022年5月本院收治的62例Hp首次根除失败PU患者为研究对象,采用奇偶数分组法分为对照组31例、研究组31例。对照组予以含铋剂四联疗法治疗,研究组予以布拉氏酵母菌辅助含铋剂四联疗法治疗。对比分析两组临床疗效、Hp根除率及复发率。分析治疗前后两组溃疡直径、临床症状评分及胃泌素相关指标、炎性因子、肠黏膜屏障功能指标水平。对比两组不良反应发生率。结果研究组总有效率、不良反应发生率、溃疡直径、临床症状评分与对照组比较无明显差异(P>0.05);研究组Hp根除率高于对照组,Hp复发率低于对照组(P<0.05);治疗后研究组血清GAS、CRP、TNF-α、IL-6、LPS、D-乳酸水平低于对照组,血清HNP、MTL水平高于对照组(P<0.05)。结论布拉氏酵母菌辅助含铋剂四联疗法治疗Hp首次根除失败PU患者,可提高Hp根除率、降低Hp复发率,并可改善胃泌素相关指标水平,抑制炎性反应,提高肠黏膜屏障功能,且具有一定安全性。
Objective To investigate the therapeutic effect of Saccharomyces Blasti assisted bismuth-containing quadruple therapy on helicobacter pylori(Hp)in patients with peptic ulcer(PU)that failed to be eradicated for the first time and its effect on Hp eradication rate and recurrence rate.Methods From February 2020 to May 2022,62 patients with PU who failed to eradicate Hp for the first time were selected as the research objects,and were divided into control group(31 cases)and study group(31 cases)by odd-even grouping method.The control group was treated with bismuth-containing quadruple therapy,while the study group was treated with Saccharomycera blasti assisted with bismuth-containing quadruple therapy.The clinical efficacy,eradication rate and recurrence rate of Hp were compared between the two groups.Ulcer diameter,clinical symptom score,gastrin-related indexes,inflammatory factors and intestinal mucosal barrier function indexes of the two groups before and after treatment were analyzed.The incidence of adverse reactions was compared between the two groups.Results There were no significant differences in the total effective rate,incidence of adverse reactions,ulcer diameter and clinical symptom score between the study group and the control group(P>0.05).The eradication rate of Hp in the study group was higher than that in the control group,and the recurrence rate of Hp in the study group was lower than that in the control group(P<0.05).After treatment,the levels of serum GAS,CRP,TNF-α,IL-6,LPS and D-lactic acid in the study group were lower than those in the control group,while the levels of serum HNP and MTL were higher than those in the control group(P<0.05).Conclusions In the treatment of PU patients who failed to eradicate Hp for the first time,quadruple therapy assisted by Saccharsaccharum blasti with bismuth can improve Hp eradication rate,reduce Hp recurrence rate,improve gastrin-related indexes,inhibit inflammatory response,and improve intestinal mucosal barrier function,with certain safety.
作者
孙育新
房太勇
SYN Yuxin;FANG Taiyong(Department of Gastroenterology,The Second Affiliated Hospital of Fujian Medical University,Quanzhou 362000,China)
出处
《中国医药指南》
2023年第33期55-58,共4页
Guide of China Medicine
关键词
消化性溃疡
幽门螺杆菌
布拉氏酵母菌
含铋剂四联疗法
炎性因子
Peptic ulcer
Helicobacter pylori
Saccharomyces bullae
Bismuth-containing quadruple therapy
Inflammatory factor
